Breast (Edinburgh, Scotland) · 2026
Risk Stratified Breast Cancer Screening: Early Outcomes and Psychological Impact from PRSONAL - a Randomized Clinical Trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pedersen Line Hjøllund, Bigaard Janne, Vejborg Ilse, Kamstrup Pia R, Andersen Berit, Yang Xin, Ficorella Lorenzo, Dennis Joe, Antoniou Antonis C, Flyger Henrik, Bojesen Stig Egil
Аннотация
PURPOSE: Risk-stratified screening for breast cancer might improve benefit-to-harm ratio, however, psychological consequences of risk communication and low-risk women's acceptance of de-escalated screening are unclear.
PATIENTS AND METHODS: We carried out a randomized clinical trial allocating women aged 50-67 years attending their routine biennial screening mammography 1:1 to a control and intervention group. Women in the control group continued the standard program without risk stratification. Women in the intervention group had their 10-year breast cancer risk assessed using the comprehensive CanRisk model. Around day 90, risk was automatically communicated as low (<2.44%), intermediate (2.44-5.14%), elevated (5.15-<7.99%), and high (≥8.00%) with suggested screening intervals of four years (low), two years (intermediate), one year (elevated) and one year (high risk), and additional investigations for those at elevated and high-risk.
RESULTS: Of the 3,949 invited women, 1,801 (46%) were enrolled. Of the intervention group, 49.6%, 38.8%, 8.4% and 3.1% were at low, intermediate, elevated and high risk, respectively. After 292 days, 3.8% (95% confidence interval = 2.3-6.1) of the low-risk women had rejected de-escalated screening. The most significant change of psychological indicators from baseline to day 180 was a 1.6-point reduction of life quality among controls (p < 0.0001), but also reductions of breast cancer worry in the low and intermediate risk groups vs. controls (-0.27, p = 0.007 and -0.33, p = 0.004).
CONCLUSION: Risk-stratified breast cancer screening is feasible and de-escalated screening acceptable for low-risk women. Automated risk communication has minimal - if any - impact on short-term psychological well-being. Final conclusions await prespecified 800 days end-of-follow-up.
PATIENTS AND METHODS: We carried out a randomized clinical trial allocating women aged 50-67 years attending their routine biennial screening mammography 1:1 to a control and intervention group. Women in the control group continued the standard program without risk stratification. Women in the intervention group had their 10-year breast cancer risk assessed using the comprehensive CanRisk model. Around day 90, risk was automatically communicated as low (<2.44%), intermediate (2.44-5.14%), elevated (5.15-<7.99%), and high (≥8.00%) with suggested screening intervals of four years (low), two years (intermediate), one year (elevated) and one year (high risk), and additional investigations for those at elevated and high-risk.
RESULTS: Of the 3,949 invited women, 1,801 (46%) were enrolled. Of the intervention group, 49.6%, 38.8%, 8.4% and 3.1% were at low, intermediate, elevated and high risk, respectively. After 292 days, 3.8% (95% confidence interval = 2.3-6.1) of the low-risk women had rejected de-escalated screening. The most significant change of psychological indicators from baseline to day 180 was a 1.6-point reduction of life quality among controls (p < 0.0001), but also reductions of breast cancer worry in the low and intermediate risk groups vs. controls (-0.27, p = 0.007 and -0.33, p = 0.004).
CONCLUSION: Risk-stratified breast cancer screening is feasible and de-escalated screening acceptable for low-risk women. Automated risk communication has minimal - if any - impact on short-term psychological well-being. Final conclusions await prespecified 800 days end-of-follow-up.